
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
How much should you reveal about yourself to your patients? To colleagues? To the state medical society? H. Steven Moffic, MD, takes a look at this issue in this video.
How much should you reveal about yourself to your patients? To colleagues? To the state medical society? H. Steven Moffic, MD, takes a look at this issue in this video.




